The DLG5 Knockout K-562 Polyclonal Cells constitute a genetically heterogeneous population of K-562 human chronic myelogenous leukemia lymphoblast-like cells with targeted disruption of the DLG5 gene via CRISPR/Cas9-mediated genome editing. This polyclonal knockout product provides a loss-of-function model for investigating DLG5 functions in hematopoietic cell contexts, avoiding artifacts associated with clonal selection. The edited cell pool retains the parental K-562 background and is suitable for population-level functional assays, including signaling studies, drug response profiling, and cell behavior analyses.
The K-562 cell line, established from a female chronic myelogenous leukemia patient in blast crisis, is a widely used model for human leukemia and hematopoietic differentiation. K-562 cells harbor the Philadelphia chromosome, producing the constitutively active BCR-ABL fusion kinase that drives uncontrolled proliferation and apoptosis resistance. As a multipotent progenitor-like line, K-562 can be induced to differentiate along erythroid, granulocytic, and megakaryocytic lineages, making it a versatile platform for studying signaling cascades, oncogenic mechanisms, and therapeutic responses in a BCR-ABL-dependent background.
DLG5 encodes a membrane-associated guanylate kinase (MAGUK) scaffold protein that localizes to tight junctions and cell?Ccell contacts, where it organizes protein complexes for epithelial polarity and barrier integrity. Transcriptionally regulated by CDX2 and the ??-catenin/TCF complex and responsive to cell density, DLG5 interacts with tight junction components ZO-1, claudin-1, occludin, JAM-A, F-actin, and the planar cell polarity protein Vangl2. These associations enable DLG5 to modulate Hippo pathway effectors YAP/TAZ and to intersect with Wnt signaling through ??-catenin, thereby influencing proliferation and migration. Consequently, DLG5 serves as a nexus coupling adhesion cues to cytoskeletal dynamics and transcriptional programs.
Although K-562 cells grow in suspension and lack mature tight junctions, MAGUK scaffold proteins can participate in hematopoietic signaling, adhesion, and migration. Expressing DLG5 in this leukemia model permits exploration of its functions beyond epithelial barriers, including potential involvement in BCR-ABL signal transduction and ??-catenin-mediated transcription. Disrupting DLG5 in this context may reveal cross-talk between oncogenic kinase signaling and polarity networks. As DLG5 dysregulation has been associated with inflammatory bowel disease, Crohn??s disease, and gastrointestinal cancers, the K-562 system also offers a platform to investigate DLG5-dependent mechanisms that may be relevant to hematopoietic roles in inflammation or metastasis.
Researchers can employ these polyclonal DLG5 knockout K-562 cells for functional studies, including western blotting and immunofluorescence to assess target depletion, flow cytometry to monitor surface markers or cell cycle, and co-immunoprecipitation to map altered protein complexes. Loss of DLG5 may impair cell adhesion and migration, assayed by fibronectin or stromal cell binding assays and transwell migration, and may modulate BCR-ABL-driven proliferation and apoptosis, measured by BrdU incorporation or annexin V staining. The model is also suited for drug sensitivity screens with tyrosine kinase inhibitors to explore whether DLG5 status influences therapeutic response. For more details, contact Ascent Research.
